Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Stock Short Interest Report for October

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 2,971 shares, an increase of 193.6% from the September 30th total of 1,012 shares. Based on an average daily volume of 31,943 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cardio Diagnostics in a report on Tuesday, September 8th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Cardio Diagnostics

A hedge fund recently bought a new stake in Cardio Diagnostics stock. Renaissance Technologies LLC acquired a new stake in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 15,348 shares of the company’s stock, valued at approximately $30,000. Renaissance Technologies LLC owned approximately 0.52% of Cardio Diagnostics as of its most recent filing with the SEC. 8.06% of the stock is owned by institutional investors.

Cardio Diagnostics Price Performance

Shares of NASDAQ CDIO traded up $0.04 during mid-day trading on Thursday, hitting $1.74. The company had a trading volume of 3,853 shares, compared to its average volume of 1,232,469. Cardio Diagnostics has a 12 month low of $0.97 and a 12 month high of $7.91. The firm has a market cap of $5.14 million, a P/E ratio of -0.59 and a beta of 2.29. The business’s 50-day simple moving average is $1.89 and its 200-day simple moving average is $2.07.

Cardio Diagnostics (NASDAQ:CDIO) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.51) EPS for the quarter. The firm had revenue of $0.01 million during the quarter. Cardio Diagnostics had a negative net margin of 43,133.33% and a negative return on equity of 82.28%.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc is a biotechnology company developing artificial intelligence-powered precision medicine products for the prevention and management of cardiovascular disease. Its approach combines genetic, epigenetic and clinical information to help identify individuals at elevated risk and support more personalized care.

The company’s product portfolio includes Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease and provide information that may guide prevention strategies.